DOCSLIB.ORG

Recommendations for Euthanasia of Experimental Animals: Part 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recommendations for Euthanasia of Experimental Animals: Part 2 WORKING PARTY REPORT Recommendations for euthanasia of experimental animals: Part 2 Working party: Mrs Bryony Close (Chair), Dr Keith Banister, Dr Vera Baumans, Dr Eva-Maria Bernoth, Dr Niall Bromage, DrJohn Bunyan, Professor Dr Wolff Erhardt, Professor Paul Flecknell, Dr Neville Gregory, Professor Dr Hansjoachim Hackbarth, Professor David Morton & Mr Clifford Warwick Correspondence to: Mrs B Close, Battleborough Croft, Battleborough Lane, Brent Knoll, Highbridge, SomersetTA9 4DS, UK This document was prepared for DGXI of the European Commission to be used with Directive 86/609/EEC of 24 November 1986, on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scienti®c purposes (No L 358, ISSN 0378-6978). It refers especially to Article 2(1) published by the European Commission in October 1995 which de®nes `humane methods of killing' as `the killing of an animal with a minimum of physical and mental suffering, depending on the species'. This is the second part of the working Contents to Part 2 party's report and comprises Section 3 of 3 Methods of euthanasia for each species the report, the list of all references group 2 cited in both parts and details of training 3.1 Fish 2 materials. The ®rst part, comprising 3.2 Amphibians 5 Sections 1 and 2 of the report together 3.3 Reptiles 8 with a reading list, was published in the 3.4 Birds 10 October 1996 issue of Laboratory Animals 3.5 Rodents 14 (30: 293±316). Reprints combining both 3.6 Rabbits 17 parts of the report will be available 3.7 Carnivores: dogs, cats, ferrets 20 from Mrs S E Wolfensohn, Supervisor of 3.8 Large mammals: pigs, sheep, Veterinary Services, University of goats, cattle, horses 23 Oxford, Veterinary Services, c/o 3.9 Non-human primates 25 University Laboratory of Physiology, 3.10 Other animals not commonly Parks Road, Oxford OXI 3PT, UK used for experiments 26 (Tel: +44(0)1865-272545, References 26 Fax: +44(0)1865-272118, Email: [email protected]). Euthanasia training materials 29 Accepted 15 February 1996 LaboratoryAnimals (1997) 31,1^32 2 Working Party Report 3 Methods of euthanasia for each internal ice crystals form. However, it must be species group remembered that cooling does not reduce the ability to feel pain. Section 1 must be consulted before consid- Overexposure to an anaesthetic is ®rst ering this section. manifested by a cessation of respiratory movements, followed by spasmodic overex- 3.1 Fish tension or ¯aring of the opercula. These are spaced 15±30 s apart at ®rst and then at longer There are over 20 000 species of ®sh with intervals. When the interval between spasms enormously varying lifestyles which makes is approximately 1 min, cardiac arrest and it very dif®cult to generalize on methods of death follow within a few minutes (Table 1). euthanasia. The methods listed below are meant as a guide and the operator must Recognition and con®rmation of death assess which is the best method for the Death may be recognized by cessation of respir- species being killed or obtain information ation (opercular movement) and cessation of from experts. A summary is given in Table 2. heartbeat(palpation).Deathshouldbecon®rmed Although ®sh may not have the same by destruction of the brain where possible. spinothalamic pathways as mammals for pain perception, there is evidence that they Larvae do feel pain and should therefore be killed Fish may be classed as oviparous, ovovivi- with the same care and consideration. parous or viviparous depending on whether All ®sh are sensitive to changes in the they produce eggs which hatch outside the physical and chemical parameters of their body, produce eggs which hatch inside the water (especially temperature, dissolved gas body, or give birth to free-living young levels, salinity, pH, etc.) but some species are much more tolerant of changes in any one of Table1 Stages of loss of consciousness, leading to these factors than are others. Therefore unless death in fish (after McFarland and Klontz, 1969) the species' response is known it is advisable to practise euthanasia in the ®sh's normal Level Designation Parameter(s) water. If drugs are used the water level should 0 Normal Reactive to external stimuli; be lowered to ensure rapid sedation but not so equilibrium and muscle tone much as to distress the ®sh before the addition normal of the agent. Dosing is always preferable to 1 Light Slight loss of reactivity to external injection as the latter technique involves sedation visual and tactile stimuli; handling the ®sh and thus induces stress. It equilibrium normal may be necessary to fast ®sh 24±48 h prior to 2 Deep Total loss of reactivity to external chemical euthanasia as this will permit more sedation stimuli except strong pressure; slight decrease in opercular rapid absorption by the gut and minimize the rate; equilibrium normal risk of regurgitation which could reduce the 3 Partial Partial loss of muscle tone; effect of the chemicals on the gill lamellae loss of swimming erratic; increased (Brown 1988). The tanks used should enable equilibrium opercular rate; reactive only to the operator to observe the ®sh and react strong tactile and vibrational quickly if there are signs of suffering. It is stimuli generally true that cooling will reduce the 4 Total loss of Total loss of muscle tone and equilibrium equilibrium; rapid opercular metabolic and locomotory processes, thus rate; reactive only to deep facilitating handling, but it is essential that pressure stimuli the normal temperature of the ®sh and its 5 Loss of reflex Total loss of reactivity; opercular degree of tolerance be considered. It is also reactivity movements very shallow; heart vital to note that in marine ®sh ice crystals rate very slow will form in the cells before the sea water 6 Medullary Opercular movements cease collapse immediately after gasping, freezes, thereby causing the ®sh extreme pain. followed by cardiac arrest In freshwater ®sh the water will freeze before Euthanasia of experimental animals 3 (larvae). For simplicity, it is considered that type drug and is the most effective way to kill all ®sh should be protected as soon as they most ®sh. It is soluble in both salt and fresh have hatched and the methods of euthanasia water. However, it is expensive and so may recommended for adults are considered deter some users, especially if they need to acceptable for larvae. Viviparous ®sh should kill large numbers of ®sh. Bicarbonate, be treated by immersion or injecting the imidazole, sodium hydrogen phospate or parent. sodium hydroxide should be added to neu- tralize the water (to pH 7.5) to reduce Adults irritation and tissue damage. It may be used Further details of methods may be found in in conjunction with quinaldine or quinaldine Section 2. sulphate to increase effectiveness. Physical methods Benzocaine (ethyl aminobenzoate) This acts in a similar way to MS-222 but has Concussion This involves a blow to the pH-independent ef®cacy. However, because back of the head and if carried out by it lowers the pH of the water, it should be experienced personnel is a humane method neutralized to pH 7.5. The breakdown time of euthanasia. Death must be con®rmed by in water is about 4 h, thus making this drug destruction of the brain. acceptable in terms of environmental con- tamination. As it is insoluble in water Cervical dislocation This is the breaking of benzocaine should ®rst be dissolved in the backbone near the head. Small to acetone before adding to water. medium ®sh are killed by inserting a rod or thumb into the mouth, holding the ®sh with Etomidate It is a potent imidazole-based the opposite hand and displacing it dorsally agent with no analgesic properties. It is (Clifford 1984). It is feasible and effective in highly soluble in water. Stress hormone small ®sh, but should be con®rmed by measurements of ®sh have indicated that exsanguination or destruction of the brain. etomidate may give fewer problems than MS- The stress caused by handling reduces the 222 (Zwart et al. 1989) and it is therefore acceptability of this method. It is not considered acceptable for euthanasia of ®sh. possible or humane in larger ®sh. Metomidate It is an imidazole-based non- Maceration Small ®sh of less than 2 cm in barbiturate hypnotic agent that has no analge- length may be humanely killed by placing sic properties. Used in overdose, this is down a waste disposal unit. considered acceptable for killing most species of ®sh. Chemical methods Quinaldine (2-methylquinoline) This is dif- Agents can be administered by dissolving the ®cult to obtain in Europe but is commonly chemical in the tank water. Water tempera- used in the USA for humane euthanasia. The tures often alter the ef®cacy of the drug and recommended dosages for euthanasia vary induction is often more rapid at higher depending upon species, temperature and temperatures. However, the temperature must water hardness. It accumulates in lipid tissues not be raised so that it causes any stress to the such as the brain and depresses the sensory ®sh. Drugs may also be administered by centres of the central nervous system. Qui- intramuscular or intraperitoneal injection. For naldine sulphate is also considered acceptable euthanasia anaesthetic drugs are generally as an effective euthanasia agent for ®sh. used at double or triple the recommended anaesthetic dose. In all cases, death must be Halothane This may be bubbled through con®rmed by destruction of the brain. the tank and causes anaesthesia. Death must be ensured by destruction of the brain.
Load more

Recommended publications
  • Electrophysiologic Evidence for Increased Endogenous Gabaergic but Not Glycinergic Inhibitory Tone in the Rat Spinal Nerve Ligation Model of Neuropathy Vesa K
    Anesthesiology 2001; 94:333–9 © 2001 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Electrophysiologic Evidence for Increased Endogenous GABAergic but Not Glycinergic Inhibitory Tone in the Rat Spinal Nerve Ligation Model of Neuropathy Vesa K. Kontinen, M.D., Ph.D.,* Louise C. Stanfa, Ph.D.,† Amlan Basu,‡ Anthony H. Dickenson, Ph.D.§ Background: Changes in the inhibitory activity mediated by There is evidence that both GABA and glycinergic inter- ␥-aminobutyric acid (GABA) and glycine, acting at spinal GABA A neurons are preferentially associated with the control of receptors and strychnine-sensitive glycine receptors, are of in- 6–9 terest in the development of neuropathic pain. There is ana- low-threshold afferent input to the spinal cord. Con- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/94/2/333/402482/0000542-200102000-00024.pdf by guest on 29 September 2021 tomic evidence for changes in these transmitter systems after sistent with this, intrathecal administration of the 10 nerve injuries, and blocking either GABAA or glycine receptors GABAA-receptor antagonist bicuculline or the glycine- has been shown to produce allodynia-like behavior in awake receptor antagonist strychnine10,11 produces segmen- normal animals. tally localized tactile allodynia-like behavior in conscious Methods: In this study, the possible changes in GABAergic and glycinergic inhibitory activity in the spinal nerve ligation rats and increased responses to mechanical stimulation 12 model of neuropathic pain were studied by comparing the in anesthetized cats. Intrathecal strychnine has also effects of the GABAA-receptor antagonist bicuculline and the been shown to produce in anesthetized rats reflex re- glycine-receptor antagonist strychnine in neuropathic rats to sponses similar to those produced by nociceptive stim- their effects in sham-operated and nonoperated control rats.
    [Show full text]
  • Standard Operating Procedure
    Biomedical Research Support Facility Standard Operating Procedure Euthanasia by Cervical Dislocation The IACUC is specifically charged with reviewing the methods of euthanasia for each research protocol to assure compliance with the recommendations contained in the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals (2013 Edition) http://www.avma.org/issues/animal_welfare/euthanasia.pdf. Since physical methods of euthanasia (such as cervical dislocation) require the most skill to perform and are most likely to be affected by human error, the AVMA recommends that such methods be used only when pharmacological methods are not appropriate. Cervical dislocation (CD) is rapid, requires neither special equipment nor transport of the animal and yields tissues uncontaminated by chemical agents. Situations where CD may be indicated in non-sedated rodents include research studies which require the harvest of drug residue- free brain tissues. The use of CD as a euthanasia method and the names of the individuals performing this procedure must be listed in the approved IACUC protocol covering the study. Acceptable Use The use of cervical dislocation in rodents is only appropriate for mice and small rats (<200g), and whenever possible the use of sedation or light anesthesia prior to euthanasia is recommended. The protocol must contain adequate scientific justification if CD must be performed on conscious animals due to study requirements. CD may also be used as a secondary means to assure death after euthanasia with CO2 or another gaseous euthanasia agent. Training Cervical dislocation (CD) euthanasia must be performed by trained individuals using appropriate equipment. The IACUC reviews all protocols using physical euthanasia techniques to assure that personnel performing the procedures are appropriately trained.
    [Show full text]
  • Insomnia and Anxiety in Older People Sleeping Pills Are Usually Not the Best Solution
    ® Insomnia and anxiety in older people Sleeping pills are usually not the best solution lmost one-third of older people in the people who take one of United States take sleeping pills. These these medicines sleep medicines are also sometimes called only a little longer and A“sedative-hypnotics” or “tranquilizers.” They better than those who affect the brain and spinal cord. don’t take a medicine. Doctors prescribe some of these medicines Sleeping pills can for sleep problems. Some of these medicines have serious side effects. also can be used to treat other conditions, such All sedative-hypnotic medicines have special as anxiety or alcohol withdrawal. Sometimes, risks for older adults. Seniors are likely to be doctors also prescribe certain anti-depressants more sensitive to the medicines’ effects than for sleep, even though that’s not what they’re younger adults. And these medicines may designed to treat. stay in older people’s bodies longer. These Most older adults should first try to treat their medicines can cause confusion and memory insomnia without medicines. According to the problems that: American Geriatrics Society, there are safer and • Increase the risk of falls and hip fractures. better ways to improve sleep or reduce anxiety. These are common causes of hospital stays Here’s why: and death in older people. Sleeping pills may not help much. • Increase the risk of car accidents. Many ads say that sleeping pills help people get a full, restful night’s sleep. But studies show that this is not exactly true in real life. On average, The new “Z” medicines also have risks.
    [Show full text]
  • Veterinary Emergency & Anaesthesia Pfizer
    AVA ECVA & AVEF Thank all their sponsors for this spring edition PARIS 2007 On VETERINARY EMERGENCY & ANAESTHESIA PFIZER MERIAL FORT DODGE BAYER BOEHRINGER MEDISUR COVETO OPTOMED HALLOWELL SCIL JANSSEN SOGEVAL KRUSSE TECHNIBELT MILA TEM The Organisatiors 7th AVEF European Meeting- 10th March 2007-ROISSY 2 AVA – ECVA Spring Meeting 2007 on Veterinary Emergency & Anesthesia 7 – 10 March 2007, Paris, France AVA PARIS 2007 — Wednesday March 7th RESIDENT DAY RUMINANT ANAESTHESIA Hyatt Regency Hotel, Roissy CDG, France K OTTO, D HOLOPHERNE, G TOUZOT 8.30 REGISTRATIONS 9.00-9.45 Specific anatomo-physiology to consider for ruminant peri-anaesthetic period K OTTO 10.00-10.30 COFFEE BREAK 10.30-11.15 Post-anaesthetic and pain management in ruminants K OTTO 11.30-12.15 Physical restraint and sedation of ruminants D HOLOPHERNE 12.30-1.30 LUNCH 1.30-2.15 Anaesthesia of Lamas & Alpagas G TOUZOT 2.30-3.15 Regional & local anaesthesia for ruminants D HOLOPHERNE 3.30-4.00 COFFEE BREAK 4.00-4.45 Pharmacology and protocols for ruminant anaesthesia G TOUZOT AVA-ECVA PARIS 2007, Veterinary Emergency & Anaesthesia, 7-10th March AVA-ECVA PARIS 2007, Veterinary Emergency & Anaesthesia, 7-10th March AVA – ECVA Spring Meeting 2007 on Veterinary Emergency & Anesthesia 7 – 10 March 2007, Paris, France Specific anatomo-physiology to consider for ruminants peri-anaesthetic period Klaus A. Otto Institut für Versuchstierkunde und Zentrales Tierlaboratorium, Medizinische Hochschule Hannover, D-30623 Hannover, Germany The suborder “ruminantia” includes members of the family “bovidae” such as cattle (bos taurus), sheep (ovis spp) and goats (capra spp). Members of the family “camelidae” (camelus spp, llama spp, vicugna spp) belong to the suborder “tylopodia” and therefore are not true ruminants.
    [Show full text]
  • Drug & Alcohol Testing Program
    Pottawattmie County Drug & Alcohol Testing Program Appendix A Table of Contents POLICY STATEMENT ...................................................................................................................................... 3 SCOPE ............................................................................................................................................................ 4 EDUCATION AND TRAINING .......................................................................................................................... 4 DESIGNATED EMPLOYER REPRESENTATIVE (DER): ....................................................................................... 5 DUTY TO COOPERATE ................................................................................................................................... 5 EMPLOYEE ADMISSION OF ALCOHOL AND CONTROLLED SUBSTANCE USE: (49 CFR Part 382.121) ... 6 PROHIBITED DRUGS AND ILLEGALLY USED CONTROLLED SUBSTANCES: ..................................................... 7 PROHIBITED BEHAVIOR AND CONDUCT: ...................................................................................................... 8 DRUG & ALCOHOL TESTING REQUIREMENTS (49 CFR, Part 40 & 382) ............................................... 10 DRUG & ALCOHOL TESTING CIRCUMSTANCES (49 CFR Part 40 & 382) .............................................. 12 A. Pre-Employment Testing: .................................................................................................... 12 B. Reasonable Suspicion Testing: .........................................................................................
    [Show full text]
  • Unnamed Document
    Mutations M287L and Q266I in the Glycine Receptor ␣1 Subunit Change Sensitivity to Volatile Anesthetics in Oocytes and Neurons, but Not the Minimal Alveolar Concentration in Knockin Mice Cecilia M. Borghese, Ph.D.,* Wei Xiong, Ph.D.,† S. Irene Oh, B.S.,‡ Angel Ho, B.S.,§ S. John Mihic, Ph.D.,ʈ Li Zhang, M.D.,# David M. Lovinger, Ph.D.,** Gregg E. Homanics, Ph.D.,†† Edmond I. Eger 2nd, M.D.,‡‡ R. Adron Harris, Ph.D.§§ ABSTRACT What We Already Know about This Topic • Inhibitory spinal glycine receptor function is enhanced by vol- Background: Volatile anesthetics (VAs) alter the function of atile anesthetics, making this a leading candidate for their key central nervous system proteins but it is not clear which, immobilizing effect if any, of these targets mediates the immobility produced by • Point mutations in the ␣1 subunit of glycine receptors have been identified that increase or decrease receptor potentiation VAs in the face of noxious stimulation. A leading candidate is by volatile anesthetics the glycine receptor, a ligand-gated ion channel important for spinal physiology. VAs variously enhance such function, and blockade of spinal glycine receptors with strychnine af- fects the minimal alveolar concentration (an anesthetic What This Article Tells Us That Is New EC50) in proportion to the degree of enhancement. • Mice harboring specific mutations in their glycine receptors Methods: We produced single amino acid mutations into that increased or decreased potentiation by volatile anesthetic in vitro did not have significantly altered changes in anesthetic the glycine receptor ␣1 subunit that increased (M287L, third potency in vivo transmembrane region) or decreased (Q266I, second trans- • These findings indicate that this glycine receptor does not me- membrane region) sensitivity to isoflurane in recombinant diate anesthetic immobility, and that other targets must be receptors, and introduced such receptors into mice.
    [Show full text]
  • Medication Guide Sedative-Hypnotic Capsules
    MEDICATION GUIDE SEDATIVE-HYPNOTIC CAPSULES C-II SECONAL SODIUM® CII (secobarbital sodium) CAPSULES, USP Rx only Read this Medication Guide before you start taking a SEDATIVE-HYPNOTIC and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment. You and your doctor should talk about the SEDATIVE-HYPNOTIC when you start taking it and at regular checkups. What is the most important information I should know about SEDATIVE-HYPNOTICS? After taking a SEDATIVE-HYPNOTIC, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night. You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you sleepy with a SEDATIVE-HYPNOTIC. Reported activities include: • driving a car ("sleep-driving") • making and eating food • talking on the phone • having sex • sleep-walking Important: 1. Take SEDATIVE-HYPNOTICS exactly as prescribed • Do not take more SEDATIVE-HYPNOTICS than prescribed. • Take the SEDATIVE-HYPNOTIC right before you get in bed, not sooner. 2. Do not take SEDATIVE-HYPNOTICS if you: • drink alcohol • take other medicines that can make you sleepy. Talk to your doctor about all of your medicines. Your doctor will tell you if you can take SEDATIVE-HYPNOTICS with your other medicines • cannot get a full night's sleep 3. Call your doctor right away if you find out that you have done any of the above activities after taking the SEDATIVE-HYPNOTIC.
    [Show full text]
  • 02/06/2019 12:05 PM Appendix 3745-21-09 Appendix A
    ACTION: Final EXISTING DATE: 02/06/2019 12:05 PM Appendix 3745-21-09 Appendix A List of Organic Chemicals for which Paragraphs (DD) and (EE) of Rule 3745-21-09 of the Administrative Code are Applicable Organic Chemical Organic Chemical Acetal Benzaldehyde Acetaldehyde Benzamide Acetaldol Benzene Acetamide Benzenedisulfonic acid Acetanilide Benzenesulfonic acid Acetic acid Benzil Acetic Anhydride Benzilic acid Acetone Benzoic acid Acetone cyanohydrin Benzoin Acetonitrile Benzonitrile Acetophenone Benzophenone Acetyl chloride Benzotrichloride Acetylene Benzoyl chloride Acrolein Benzyl alcohol Acrylamide Benzylamine Acrylic acid Benzyl benzoate Acrylonitrile Benzyl chloride Adipic acid Benzyl dichloride Adiponitrile Biphenyl Alkyl naphthalenes Bisphenol A Allyl alcohol Bromobenzene Allyl chloride Bromonaphthalene Aminobenzoic acid Butadiene Aminoethylethanolamine 1-butene p-aminophenol n-butyl acetate Amyl acetates n-butyl acrylate Amyl alcohols n-butyl alcohol Amyl amine s-butyl alcohol Amyl chloride t-butyl alcohol Amyl mercaptans n-butylamine Amyl phenol s-butylamine Aniline t-butylamine Aniline hydrochloride p-tertbutyl benzoic acid Anisidine 1,3-butylene glycol Anisole n-butyraldehyde Anthranilic acid Butyric acid Anthraquinone Butyric anhydride Butyronitrile Caprolactam APPENDIX p(183930) pa(324943) d: (715700) ra(553210) print date: 02/06/2019 12:05 PM 3745-21-09, Appendix A 2 Carbon disulfide Cyclohexene Carbon tetrabromide Cyclohexylamine Carbon tetrachloride Cyclooctadiene Cellulose acetate Decanol Chloroacetic acid Diacetone alcohol
    [Show full text]
  • Fatal Basilar Artery Occlusion Following Cervical Spine Injury
    Paraplegia 17 (1979-80) 280-283 FATAL BASILAR ARTERY OCCLUSION FOLLOWING CERVICAL SPINE INJURY By ROBERT M. WOOLSEY, M.D. and HYUNG D. CHUNG, M.D. Spinal Cord Injury Service, St Louis Veterans Administration Medical Center and The Department of Neurology and Neuropathology of St. Louis University St Louis, Missouri 63I25, U.S.A. DESPITE the intimate relationship between the cervical spine and vertebral artery, symptoms referable to vertebral artery damage have rarely been reported in association with cervical spine fractures. The following case of fatal basilar artery occlusion in a patient with vertebral artery thrombosis at the site of a cervical spine fracture is somewhat unique. Case Report A 31-year-old man was injured in an automobile accident on 2715178. When examined shortly thereafter, he was found to have no sensation or movement in his lower extremities. He had intact pain sensation in his right thumb and index finger and along the lateral aspect of his arm and forearm but loss of pain sensation in his other fingers and the medial aspect of his arm and forearm. He was able to flex his right arm and abduct his right shoulder with normal strength. He could extend his right wrist with about 25 per cent normal strength. The remaining muscles of the right arm were paralysed. The left arm was completely immobile, cold and without arterial pulses. Cervical spine X-rays were 'normal'. X-rays of the chest showed fractures involving the second, fourth and fifth ribs, the clavicle and scapula on the left side. There was haziness of the left upper lobe of the lung.
    [Show full text]
  • Environmental Properties of Chemicals Volume 2
    1 t ENVIRONMENTAL 1 PROTECTION Esa Nikunen . Riitta Leinonen Birgit Kemiläinen • Arto Kultamaa Environmental properties of chemicals Volume 2 1 O O O O O O O O OO O OOOOOO Ol OIOOO FINNISH ENVIRONMENT INSTITUTE • EDITA Esa Nikunen e Riitta Leinonen Birgit Kemiläinen • Arto Kultamaa Environmental properties of chemicals Volume 2 HELSINKI 1000 OlO 00000001 00000000000000000 Th/s is a second revfsed version of Environmental Properties of Chemica/s, published by VAPK-Pub/ishing and Ministry of Environment, Environmental Protection Department as Research Report 91, 1990. The pubiication is also available as a CD ROM version: EnviChem 2.0, a PC database runniny under Windows operating systems. ISBN 951-7-2967-2 (publisher) ISBN 952-7 1-0670-0 (co-publisher) ISSN 1238-8602 Layout: Pikseri Julkaisupalvelut Cover illustration: Jussi Hirvi Edita Ltd. Helsinki 2000 Environmental properties of chemicals Volume 2 _____ _____________________________________________________ Contents . VOLUME ONE 1 Contents of the report 2 Environmental properties of chemicals 3 Abbreviations and explanations 7 3.1 Ways of exposure 7 3.2 Exposed species 7 3.3 Fffects________________________________ 7 3.4 Length of exposure 7 3.5 Odour thresholds 8 3.6 Toxicity endpoints 9 3.7 Other abbreviations 9 4 Listofexposedspecies 10 4.1 Mammais 10 4.2 Plants 13 4.3 Birds 14 4.4 Insects 17 4.5 Fishes 1$ 4.6 Mollusca 22 4.7 Crustaceans 23 4.8 Algae 24 4.9 Others 25 5 References 27 Index 1 List of chemicals in alphabetical order - 169 Index II List of chemicals in CAS-number order
    [Show full text]
  • AVMA Guidelines for the Euthanasia of Animals: 2020 Edition*
    AVMA Guidelines for the Euthanasia of Animals: 2020 Edition* Members of the Panel on Euthanasia Steven Leary, DVM, DACLAM (Chair); Fidelis Pharmaceuticals, High Ridge, Missouri Wendy Underwood, DVM (Vice Chair); Indianapolis, Indiana Raymond Anthony, PhD (Ethicist); University of Alaska Anchorage, Anchorage, Alaska Samuel Cartner, DVM, MPH, PhD, DACLAM (Lead, Laboratory Animals Working Group); University of Alabama at Birmingham, Birmingham, Alabama Temple Grandin, PhD (Lead, Physical Methods Working Group); Colorado State University, Fort Collins, Colorado Cheryl Greenacre, DVM, DABVP (Lead, Avian Working Group); University of Tennessee, Knoxville, Tennessee Sharon Gwaltney-Brant, DVM, PhD, DABVT, DABT (Lead, Noninhaled Agents Working Group); Veterinary Information Network, Mahomet, Illinois Mary Ann McCrackin, DVM, PhD, DACVS, DACLAM (Lead, Companion Animals Working Group); University of Georgia, Athens, Georgia Robert Meyer, DVM, DACVAA (Lead, Inhaled Agents Working Group); Mississippi State University, Mississippi State, Mississippi David Miller, DVM, PhD, DACZM, DACAW (Lead, Reptiles, Zoo and Wildlife Working Group); Loveland, Colorado Jan Shearer, DVM, MS, DACAW (Lead, Animals Farmed for Food and Fiber Working Group); Iowa State University, Ames, Iowa Tracy Turner, DVM, MS, DACVS, DACVSMR (Lead, Equine Working Group); Turner Equine Sports Medicine and Surgery, Stillwater, Minnesota Roy Yanong, VMD (Lead, Aquatics Working Group); University of Florida, Ruskin, Florida AVMA Staff Consultants Cia L. Johnson, DVM, MS, MSc; Director,
    [Show full text]
  • Evaluating the Translational Potential of Progesterone Treatment Following
    Wong et al. BMC Neuroscience 2014, 15:131 http://www.biomedcentral.com/1471-2202/15/131 RESEARCH ARTICLE Open Access Evaluating the translational potential of progesterone treatment following transient cerebral ischaemia in male mice Raymond Wong1, Claire L Gibson2*, David A Kendall3 and Philip MW Bath1 Abstract Background: Progesterone is neuroprotective in numerous preclinical CNS injury models including cerebral ischaemia. The aim of this study was two-fold; firstly, we aimed to determine whether progesterone delivery via osmotic mini-pump would confer neuroprotective effects and whether such neuroprotection could be produced in co-morbid animals. Results: Animals underwent transient middle cerebral artery occlusion. At the onset of reperfusion, mice were injected intraperitoneally with progesterone (8 mg/kg in dimethylsulfoxide). Adult and aged C57 Bl/6 mice were dosed additionally with subcutaneous infusion (1.0 μl/h of a 50 mg/ml progesterone solution) via implanted osmotic minipumps. Mice were allowed to survive for up to 7 days post-ischaemia and assessed for general well-being (mass loss and survival), neurological score, foot fault and t-maze performance. Progesterone reduced neurological deficit [F(1,2) = 5.38, P = 0.027] and number of contralateral foot-faults [F(1,2) = 7.36, P = 0.0108] in adult, but not aged animals, following ischaemia. In hypertensive animals, progesterone treatment lowered neurological deficit [F(1,6) = 18.31, P = 0.0001], reduced contralateral/ipsilateral alternation ratio % [F(1,2) = 17.05, P = 0.0006] and time taken to complete trials [F(1,2) = 15.92, P = 0.0009] for t-maze. Conclusion: Post-ischemic progesterone administration via mini-pump delivery is effective in conferring functional improvement in a transient MCAO model in adult mice.
    [Show full text]